Viking Therapeutics Stock Plummets, Future Uncertain
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: Fool
- Significant Stock Decline: Viking Therapeutics' stock has plummeted from nearly $100 to below $30, indicating a sharp decline in investor confidence, particularly as competitors like Novo Nordisk and Eli Lilly continue to launch new drugs.
- Disappointing Clinical Trial Results: Although VK2735 showed promising results in early trials, subsequent data revealed worse-than-expected side effects, leading to a negative shift in public perception and investor sentiment.
- Increasing Cash Burn: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face the risk of share dilution if it fails to raise additional funds soon, further undermining shareholder confidence.
- Intensifying Market Competition: As Viking strives to bring its weight-loss drug to market, larger competitors like Novo Nordisk and Eli Lilly are developing more potent new treatments, making the future market landscape increasingly challenging for Viking and casting doubt on its prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.680
Low
70.00
Averages
97.00
High
125.00
Current: 30.680
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Emerges as Potential Acquisition Target for Big Pharma
- Obesity Drug Market Potential: Viking Therapeutics' VK2735 achieved an average weight loss of 12.2% in a recent Phase 2 oral obesity study over 13 weeks, showcasing strong efficacy that attracts acquisition interest from big pharma, especially as the obesity drug market is projected to exceed $100 billion.
- Clinical Trial Progress: The Phase 3 VANQUISH obesity study for VK2735 is fully enrolled, with management expecting to initiate Phase 3 trials for the oral tablet later this year, laying a foundation for future revenue growth and enhancing its position in a competitive market.
- Financial Health: As of Q1 2026, Viking holds approximately $603 million in cash and investments, which is expected to fund operations into 2028, providing flexibility in acquisition negotiations and reducing immediate financing pressure.
- Market Valuation Discrepancy: Despite Viking's market capitalization being around $3 billion, significantly lower than analysts' price targets of $95 for VK2735, its potential competitiveness in the obesity drug sector makes it an attractive acquisition candidate for larger pharmaceutical companies.
See More
Viking Therapeutics Stock Plummets, Future Uncertain
- Significant Stock Decline: Viking Therapeutics' stock has plummeted from nearly $100 to below $30, indicating a sharp decline in investor confidence, particularly as competitors like Novo Nordisk and Eli Lilly continue to launch new drugs.
- Disappointing Clinical Trial Results: Although VK2735 showed promising results in early trials, subsequent data revealed worse-than-expected side effects, leading to a negative shift in public perception and investor sentiment.
- Increasing Cash Burn: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face the risk of share dilution if it fails to raise additional funds soon, further undermining shareholder confidence.
- Intensifying Market Competition: As Viking strives to bring its weight-loss drug to market, larger competitors like Novo Nordisk and Eli Lilly are developing more potent new treatments, making the future market landscape increasingly challenging for Viking and casting doubt on its prospects.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
Viking Therapeutics Emerges as Potential Acquisition Target in Biotech
- Obesity Drug Market Potential: Viking Therapeutics' VK2735 demonstrated strong efficacy in a recent Phase 2 oral obesity study, with patients achieving an average weight loss of 12.2% over 13 weeks, indicating its competitive edge in the obesity market and likely attracting interest from large pharmaceutical companies.
- Clinical Trial Progress: Viking's Phase 3 VANQUISH obesity studies are fully enrolled, and management expects to initiate Phase 3 trials for the oral formulation later this year, which will further validate VK2735's market potential and drive up the company's valuation.
- Strong Financial Position: As of Q1 2026, Viking holds approximately $603 million in cash and investments, which is expected to fund operations into 2028, providing the company with flexibility during acquisition negotiations and reducing immediate financing pressures.
- Clear Acquisition Logic: If a larger pharmaceutical company believes VK2735 can compete effectively in the obesity and diabetes markets, acquiring Viking could be less costly than waiting for the asset to reach commercialization, although the success of such acquisitions remains unpredictable.
See More
Analysis of Biotech Companies' Prospects
- Abivax's Potential: Abivax's obefazimod has shown promising results in a phase 3 trial for moderate-to-severe ulcerative colitis, with 47.3% of patients having inadequate responses to prior therapies, indicating strong efficacy in a competitive market; if approved, the stock could potentially double by 2030.
- Valuation Risks: Currently valued at €8.44 billion ($9.8 billion), Abivax's market cap reflects high expectations for obefazimod's commercial potential, but if the leading candidate fails to meet these expectations, the stock could plummet, highlighting significant investment risks.
- Viking's Market Positioning: Viking Therapeutics is developing VK2735 as a weight-loss drug, with data from phase 3 trials expected in 12 to 18 months; strong results could lead to substantial stock price increases, particularly in the rapidly growing weight-loss market.
- Diverse Strategy: Viking is developing both subcutaneous and oral formulations of VK2735, showcasing strategic flexibility, especially as newly approved oral weight-loss medications attract new patients, potentially opening new revenue streams in the coming years.
See More
Viking Therapeutics Emerges as Potential Acquisition Target for Big Pharma
- Obesity Drug Market Potential: Viking Therapeutics' VK2735 achieved an average weight loss of 12.2% in a recent Phase 2 oral obesity study over 13 weeks, showcasing strong efficacy that attracts acquisition interest from big pharma, especially as the obesity drug market is projected to exceed $100 billion.
- Clinical Trial Progress: The Phase 3 VANQUISH obesity study for VK2735 is fully enrolled, with management expecting to initiate Phase 3 trials for the oral tablet later this year, laying a foundation for future revenue growth and enhancing its position in a competitive market.
- Financial Health: As of Q1 2026, Viking holds approximately $603 million in cash and investments, which is expected to fund operations into 2028, providing flexibility in acquisition negotiations and reducing immediate financing pressure.
- Market Valuation Discrepancy: Despite Viking's market capitalization being around $3 billion, significantly lower than analysts' price targets of $95 for VK2735, its potential competitiveness in the obesity drug sector makes it an attractive acquisition candidate for larger pharmaceutical companies.
See More
Viking Therapeutics Stock Plummets, Future Uncertain
- Significant Stock Decline: Viking Therapeutics' stock has plummeted from nearly $100 to below $30, indicating a sharp decline in investor confidence, particularly as competitors like Novo Nordisk and Eli Lilly continue to launch new drugs.
- Disappointing Clinical Trial Results: Although VK2735 showed promising results in early trials, subsequent data revealed worse-than-expected side effects, leading to a negative shift in public perception and investor sentiment.
- Increasing Cash Burn: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face the risk of share dilution if it fails to raise additional funds soon, further undermining shareholder confidence.
- Intensifying Market Competition: As Viking strives to bring its weight-loss drug to market, larger competitors like Novo Nordisk and Eli Lilly are developing more potent new treatments, making the future market landscape increasingly challenging for Viking and casting doubt on its prospects.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
Viking Therapeutics Emerges as Potential Acquisition Target in Biotech
- Obesity Drug Market Potential: Viking Therapeutics' VK2735 demonstrated strong efficacy in a recent Phase 2 oral obesity study, with patients achieving an average weight loss of 12.2% over 13 weeks, indicating its competitive edge in the obesity market and likely attracting interest from large pharmaceutical companies.
- Clinical Trial Progress: Viking's Phase 3 VANQUISH obesity studies are fully enrolled, and management expects to initiate Phase 3 trials for the oral formulation later this year, which will further validate VK2735's market potential and drive up the company's valuation.
- Strong Financial Position: As of Q1 2026, Viking holds approximately $603 million in cash and investments, which is expected to fund operations into 2028, providing the company with flexibility during acquisition negotiations and reducing immediate financing pressures.
- Clear Acquisition Logic: If a larger pharmaceutical company believes VK2735 can compete effectively in the obesity and diabetes markets, acquiring Viking could be less costly than waiting for the asset to reach commercialization, although the success of such acquisitions remains unpredictable.
See More
Analysis of Biotech Companies' Prospects
- Abivax's Potential: Abivax's obefazimod has shown promising results in a phase 3 trial for moderate-to-severe ulcerative colitis, with 47.3% of patients having inadequate responses to prior therapies, indicating strong efficacy in a competitive market; if approved, the stock could potentially double by 2030.
- Valuation Risks: Currently valued at €8.44 billion ($9.8 billion), Abivax's market cap reflects high expectations for obefazimod's commercial potential, but if the leading candidate fails to meet these expectations, the stock could plummet, highlighting significant investment risks.
- Viking's Market Positioning: Viking Therapeutics is developing VK2735 as a weight-loss drug, with data from phase 3 trials expected in 12 to 18 months; strong results could lead to substantial stock price increases, particularly in the rapidly growing weight-loss market.
- Diverse Strategy: Viking is developing both subcutaneous and oral formulations of VK2735, showcasing strategic flexibility, especially as newly approved oral weight-loss medications attract new patients, potentially opening new revenue streams in the coming years.
See More
